Review



sciflexarrayer s3 noncontact microarray  (SCIENION)


Bioz Verified Symbol SCIENION is a verified supplier
Bioz Manufacturer Symbol SCIENION manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    SCIENION sciflexarrayer s3 noncontact microarray
    Sciflexarrayer S3 Noncontact Microarray, supplied by SCIENION, used in various techniques. Bioz Stars score: 96/100, based on 308 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sciflexarrayer s3 noncontact microarray/product/SCIENION
    Average 96 stars, based on 308 article reviews
    sciflexarrayer s3 noncontact microarray - by Bioz Stars, 2026-04
    96/100 stars

    Images



    Similar Products

    96
    SCIENION sciflexarrayer s3 noncontact microarray
    Sciflexarrayer S3 Noncontact Microarray, supplied by SCIENION, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sciflexarrayer s3 noncontact microarray/product/SCIENION
    Average 96 stars, based on 1 article reviews
    sciflexarrayer s3 noncontact microarray - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    SCIENION noncontact microarray printer
    <t>Microarray</t> analysis reveals the effects of GFAP mAb treatment on key inflammatory mediators in glaucomatous retina. ( A - C ) The expression of TLR4 and S100A8 was significantly downregulated by 25–50 µg GFAP mAb treatment compared to the vehicle. The marker for microglial activation, CD68, was significantly decreased in the 25 µg GFAP mAb treatment group. ( D - F ) Proteins of the inflammasome pathway, NLRP3, GSDMD and Caspase-1 were significantly downregulated in the 25 µg GFAP mAb treatment group. With the 50 µg dose, these protein expressions showed a similar downward trend, but without statistical significance. ( G ) Expression profiling of inflammation-associated mediators showed that 25 µg GFAP mAb significantly decreased pro-inflammatory factors (TNF-α, IL-1β, IL-8, MMP9, and IFN-γ), and increased the anti-inflammatory cytokine IL-10 compared to the vehicle group. In contrast, the 50 µg dose significantly reduced IFN-γ only. ( H ) Representative images of spots showing IL-1β levels in the subarrays for each group. Image analysis was conducted with Imagene software, using the median intensity from each spot to calculate the mean of the triplicate spots for each marker. For CD68 and TLR4, due to significant heterogeneity in SDs, statistical analysis was performed using Welch’s ANOVA followed by the Tamhane T2 post hoc test. All other data were analyzed using one-way ANOVA with Tukey’s post hoc test. Data are presented as the mean ± SD; n = 4 per group; * p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. TLR4 – Toll-Like Receptor 4. S100A8 – S100 Calcium Binding Protein A8. NLRP3 – NLR Family Pyrin Domain Containing 3. GSDMD – Gasdermin D
    Noncontact Microarray Printer, supplied by SCIENION, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/noncontact microarray printer/product/SCIENION
    Average 96 stars, based on 1 article reviews
    noncontact microarray printer - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    SCIENION noncontact microarray printing robot
    <t>Microarray</t> analysis reveals the effects of GFAP mAb treatment on key inflammatory mediators in glaucomatous retina. ( A - C ) The expression of TLR4 and S100A8 was significantly downregulated by 25–50 µg GFAP mAb treatment compared to the vehicle. The marker for microglial activation, CD68, was significantly decreased in the 25 µg GFAP mAb treatment group. ( D - F ) Proteins of the inflammasome pathway, NLRP3, GSDMD and Caspase-1 were significantly downregulated in the 25 µg GFAP mAb treatment group. With the 50 µg dose, these protein expressions showed a similar downward trend, but without statistical significance. ( G ) Expression profiling of inflammation-associated mediators showed that 25 µg GFAP mAb significantly decreased pro-inflammatory factors (TNF-α, IL-1β, IL-8, MMP9, and IFN-γ), and increased the anti-inflammatory cytokine IL-10 compared to the vehicle group. In contrast, the 50 µg dose significantly reduced IFN-γ only. ( H ) Representative images of spots showing IL-1β levels in the subarrays for each group. Image analysis was conducted with Imagene software, using the median intensity from each spot to calculate the mean of the triplicate spots for each marker. For CD68 and TLR4, due to significant heterogeneity in SDs, statistical analysis was performed using Welch’s ANOVA followed by the Tamhane T2 post hoc test. All other data were analyzed using one-way ANOVA with Tukey’s post hoc test. Data are presented as the mean ± SD; n = 4 per group; * p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. TLR4 – Toll-Like Receptor 4. S100A8 – S100 Calcium Binding Protein A8. NLRP3 – NLR Family Pyrin Domain Containing 3. GSDMD – Gasdermin D
    Noncontact Microarray Printing Robot, supplied by SCIENION, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/noncontact microarray printing robot/product/SCIENION
    Average 96 stars, based on 1 article reviews
    noncontact microarray printing robot - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    SCIENION sciflexarrayer s3 noncontact microarray printer
    <t>Microarray</t> analysis reveals the effects of GFAP mAb treatment on key inflammatory mediators in glaucomatous retina. ( A - C ) The expression of TLR4 and S100A8 was significantly downregulated by 25–50 µg GFAP mAb treatment compared to the vehicle. The marker for microglial activation, CD68, was significantly decreased in the 25 µg GFAP mAb treatment group. ( D - F ) Proteins of the inflammasome pathway, NLRP3, GSDMD and Caspase-1 were significantly downregulated in the 25 µg GFAP mAb treatment group. With the 50 µg dose, these protein expressions showed a similar downward trend, but without statistical significance. ( G ) Expression profiling of inflammation-associated mediators showed that 25 µg GFAP mAb significantly decreased pro-inflammatory factors (TNF-α, IL-1β, IL-8, MMP9, and IFN-γ), and increased the anti-inflammatory cytokine IL-10 compared to the vehicle group. In contrast, the 50 µg dose significantly reduced IFN-γ only. ( H ) Representative images of spots showing IL-1β levels in the subarrays for each group. Image analysis was conducted with Imagene software, using the median intensity from each spot to calculate the mean of the triplicate spots for each marker. For CD68 and TLR4, due to significant heterogeneity in SDs, statistical analysis was performed using Welch’s ANOVA followed by the Tamhane T2 post hoc test. All other data were analyzed using one-way ANOVA with Tukey’s post hoc test. Data are presented as the mean ± SD; n = 4 per group; * p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. TLR4 – Toll-Like Receptor 4. S100A8 – S100 Calcium Binding Protein A8. NLRP3 – NLR Family Pyrin Domain Containing 3. GSDMD – Gasdermin D
    Sciflexarrayer S3 Noncontact Microarray Printer, supplied by SCIENION, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sciflexarrayer s3 noncontact microarray printer/product/SCIENION
    Average 96 stars, based on 1 article reviews
    sciflexarrayer s3 noncontact microarray printer - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    Image Search Results


    Microarray analysis reveals the effects of GFAP mAb treatment on key inflammatory mediators in glaucomatous retina. ( A - C ) The expression of TLR4 and S100A8 was significantly downregulated by 25–50 µg GFAP mAb treatment compared to the vehicle. The marker for microglial activation, CD68, was significantly decreased in the 25 µg GFAP mAb treatment group. ( D - F ) Proteins of the inflammasome pathway, NLRP3, GSDMD and Caspase-1 were significantly downregulated in the 25 µg GFAP mAb treatment group. With the 50 µg dose, these protein expressions showed a similar downward trend, but without statistical significance. ( G ) Expression profiling of inflammation-associated mediators showed that 25 µg GFAP mAb significantly decreased pro-inflammatory factors (TNF-α, IL-1β, IL-8, MMP9, and IFN-γ), and increased the anti-inflammatory cytokine IL-10 compared to the vehicle group. In contrast, the 50 µg dose significantly reduced IFN-γ only. ( H ) Representative images of spots showing IL-1β levels in the subarrays for each group. Image analysis was conducted with Imagene software, using the median intensity from each spot to calculate the mean of the triplicate spots for each marker. For CD68 and TLR4, due to significant heterogeneity in SDs, statistical analysis was performed using Welch’s ANOVA followed by the Tamhane T2 post hoc test. All other data were analyzed using one-way ANOVA with Tukey’s post hoc test. Data are presented as the mean ± SD; n = 4 per group; * p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. TLR4 – Toll-Like Receptor 4. S100A8 – S100 Calcium Binding Protein A8. NLRP3 – NLR Family Pyrin Domain Containing 3. GSDMD – Gasdermin D

    Journal: Journal of Neuroinflammation

    Article Title: Targeting glial fibrillary acidic protein in glaucoma: a monoclonal antibody approach to modulate glial reactivity and neuroinflammation for neuroprotection

    doi: 10.1186/s12974-025-03482-8

    Figure Lengend Snippet: Microarray analysis reveals the effects of GFAP mAb treatment on key inflammatory mediators in glaucomatous retina. ( A - C ) The expression of TLR4 and S100A8 was significantly downregulated by 25–50 µg GFAP mAb treatment compared to the vehicle. The marker for microglial activation, CD68, was significantly decreased in the 25 µg GFAP mAb treatment group. ( D - F ) Proteins of the inflammasome pathway, NLRP3, GSDMD and Caspase-1 were significantly downregulated in the 25 µg GFAP mAb treatment group. With the 50 µg dose, these protein expressions showed a similar downward trend, but without statistical significance. ( G ) Expression profiling of inflammation-associated mediators showed that 25 µg GFAP mAb significantly decreased pro-inflammatory factors (TNF-α, IL-1β, IL-8, MMP9, and IFN-γ), and increased the anti-inflammatory cytokine IL-10 compared to the vehicle group. In contrast, the 50 µg dose significantly reduced IFN-γ only. ( H ) Representative images of spots showing IL-1β levels in the subarrays for each group. Image analysis was conducted with Imagene software, using the median intensity from each spot to calculate the mean of the triplicate spots for each marker. For CD68 and TLR4, due to significant heterogeneity in SDs, statistical analysis was performed using Welch’s ANOVA followed by the Tamhane T2 post hoc test. All other data were analyzed using one-way ANOVA with Tukey’s post hoc test. Data are presented as the mean ± SD; n = 4 per group; * p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. TLR4 – Toll-Like Receptor 4. S100A8 – S100 Calcium Binding Protein A8. NLRP3 – NLR Family Pyrin Domain Containing 3. GSDMD – Gasdermin D

    Article Snippet: Briefly, the microarray was prepared using a noncontact microarray printer (SciFLEXARRAYER S3; Scienion, Berlin, Germany).

    Techniques: Microarray, Expressing, Marker, Activation Assay, Software, Binding Assay